X-linked agammaglobulinemia

17,637views

X-linked agammaglobulinemia

Cardiovascular

Cardiovascular

Development of the cardiovascular system
Anatomy of the heart
Anatomy of the superior mediastinum
Anatomy of the inferior mediastinum
Anatomy of the coronary circulation
Anatomy clinical correlates: Heart
Anatomy clinical correlates: Mediastinum
Pressures in the cardiovascular system
Hyperlipidemia
Down syndrome (Trisomy 21)
Edwards syndrome (Trisomy 18)
Patau syndrome (Trisomy 13)
Fragile X syndrome
Huntington disease
Myotonic dystrophy
Friedreich ataxia
Turner syndrome
Klinefelter syndrome
Prader-Willi syndrome
Angelman syndrome
Beckwith-Wiedemann syndrome
Cri du chat syndrome
Williams syndrome
Alagille syndrome (NORD)
Achondroplasia
Polycystic kidney disease
Familial adenomatous polyposis
Familial hypercholesterolemia
Hereditary spherocytosis
Li-Fraumeni syndrome
Marfan syndrome
Multiple endocrine neoplasia
Neurofibromatosis
Tuberous sclerosis
von Hippel-Lindau disease
Albinism
Cystic fibrosis
Gaucher disease (NORD)
Glycogen storage disease type I
Glycogen storage disease type II (NORD)
Glycogen storage disease type III
Glycogen storage disease type IV
Glycogen storage disease type V
Hemochromatosis
Mucopolysaccharide storage disease type 1 (Hurler syndrome) (NORD)
Krabbe disease
Leukodystrophy
Niemann-Pick disease types A and B (NORD)
Niemann-Pick disease type C
Primary ciliary dyskinesia
Sickle cell disease (NORD)
Tay-Sachs disease (NORD)
Alpha-thalassemia
Beta-thalassemia
Wilson disease
Alport syndrome
X-linked agammaglobulinemia
Fabry disease (NORD)
Glucose-6-phosphate dehydrogenase (G6PD) deficiency
Hemophilia
Mucopolysaccharide storage disease type 2 (Hunter syndrome) (NORD)
Lesch-Nyhan syndrome
Muscular dystrophy
Ornithine transcarbamylase deficiency
Wiskott-Aldrich syndrome
Mitochondrial myopathy
Autosomal trisomies: Pathology review
Muscular dystrophies and mitochondrial myopathies: Pathology review
Miscellaneous genetic disorders: Pathology review
Hypertension
Baroreceptors
Lipid-lowering medications: Statins
Miscellaneous lipid-lowering medications
Lipid-lowering medications: Fibrates
Microcirculation and Starling forces
ECG basics
ECG intervals
ECG axis
ECG normal sinus rhythm
ECG QRS transition
ECG rate and rhythm
ECG cardiac hypertrophy and enlargement
ECG cardiac infarction and ischemia
Renin-angiotensin-aldosterone system
Myocardial infarction
Tetralogy of Fallot
Atrial septal defect
Ventricular septal defect
Thiazide and thiazide-like diuretics
Adrenergic antagonists: Beta blockers
Calcium channel blockers
ACE inhibitors, ARBs and direct renin inhibitors
Abnormal heart sounds
Normal heart sounds
Action potentials in myocytes
Excitability and refractory periods
Action potentials in pacemaker cells
Cardiac excitation-contraction coupling
Cardiac conduction velocity
Cardiac conduction system
Persistent truncus arteriosus
Atrial fibrillation
Ventricular tachycardia
Ventricular fibrillation
Atrioventricular block
Bundle branch block
Heart failure
Long QT syndrome and Torsade de pointes
Aortic valve disease
Mitral valve disease
Loop diuretics
Peripheral artery disease

Flashcards

X-linked agammaglobulinemia

0 of 6 complete

Questions

USMLE® Step 1 style questions USMLE

0 of 1 complete

A 2 year-old boy is brought to the emergency department for evaluation of fever, cough, and shortness of breath. The patient has a history of recurrent infections including otitis media, pneumonia, and erysipelas. He recently recovered from a prolonged course of diarrhea due to infection with Giardia. Temperature is 38.7 C° (101.7 F°), pulse is 140/min, respirations are 55/min and blood pressure is 100/50 mmHg. Physical examination shows small bilateral tonsils and rales in the right lower lobe of the lung. The patient is at 25th percentile for height and 10th percentile for weight. Intraepidermal injection of Candida antigens results in the appearance of a large indurated nodule within 48 hours. Flow cytometry of the patient’s peripheral blood smear demonstrates absence of CD19+ cells. Impairment of which of the following immunoprotective mechanisms is most likely contributing to this patient’s disease process? 

Transcript

Watch video only

With X-linked agammaglobulinemia, or XLA for short, gamma globulin is another name for immunoglobulin, which is another name for antibodies, a- means without, and -emia refers to the blood.

So this is a disease where there aren’t any antibodies in the blood, and X-linked means that it’s caused by a gene mutation on the X chromosome.

Now, normally, immunoglobulins are secreted into the blood by plasma cells, which are fully matured or differentiated B cells, a type of immune cell.

Way before that ever happens, though, those B cells start out in the bone marrow as pluripotent stem cells, pluripotent meaning that they can develop into a number of different types of cells.

But to become a B cell, first that pluripotent stem cell differentiates into a lymphoid precursor cell, then a pro-B cell, then a pre-B cell, then an immature B cell which migrates from the bone marrow to the spleen, where it becomes a mature or naive B cell, which after being exposed to the right antigen, moves into the blood or lymph and becomes an antibody-secreting plasma cell.

In XLA, this maturation process stops at the pre-B cell stage.

Why does it do that? Well, by the immature B cell stage, it has a B cell receptor, which is a membrane-bound antibody, specifically an immunoglobulin M or IgM.

But in the Pre- and Pro-B cell stages, this B cell receptor’s still being assembled, once it’s finished, it’s made up of heavy chain and light chain protein subunits, and the heavy chains are put together first.

Since it hasn’t been fully assembled yet, this IgM’s known as a pre-B cell receptor.

Now, an enzyme called bruton’s tyrosine kinase is super important for both the development and normal functioning of the B cell receptor.

With XLA, though, there’s a mutation in the BTK gene which makes the BTK enzyme ineffective.

And because of this ineffective BTK enzyme, the B cell maturation process gets stopped at this Pre-B cell stage, meaning no B cells leave the bone marrow, so ultimately people with XLA completely lack or have far fewer circulating B cells, and since B cells turn into plasma cells, which produce immunoglobulins or antibodies, they also lack circulating antibodies of all classes.

In the bone marrow, they might have normal or decreased levels of pre-B cells, with IgM heavy chains found in their cytoplasm.

Key Takeaways

X-linked agammaglobulinemia (XLA) is an x-linked genetic disorder of the immune system caused by mutations in the BTK (Bruton's tyrosine kinase) gene. XLA primarily affects males, as they only have one X chromosome, while females have two and are typically carriers of the mutated gene. Individuals with XLA have a deficiency in B cells. This results in an inability to mount an effective immune response against bacterial infections, leading to recurrent and often severe infections, especially of the respiratory tract and ears. The symptoms of XLA typically appear in early childhood, and affected individuals may experience recurrent bacterial infections, chronic diarrhea, and failure to thrive.

Sources

  1. "Harrison's Principles of Internal Medicine, Twentieth Edition (Vol.1 & Vol.2)" McGraw-Hill Education / Medical (2018)
  2. "CURRENT Medical Diagnosis and Treatment 2020" McGraw-Hill Education / Medical (2019)
  3. "Yen & Jaffe's Reproductive Endocrinology" Saunders W.B. (2018)
  4. "Bates' Guide to Physical Examination and History Taking" LWW (2016)
  5. "Robbins Basic Pathology" Elsevier (2017)
  6. "X-Linked Agammaglobulinemia Patients Are Not Infected with Epstein-Barr Virus: Implications for the Biology of the Virus" Journal of Virology (1999)
  7. "Autoimmunity in Primary Immunodeficiency Disorders: An Updated Review on Pathogenic and Clinical Implications" Journal of Clinical Medicine (2021)
  8. "Peripheral B Cell Deficiency and Predisposition to Viral Infections: The Paradigm of Immune Deficiencies" Frontiers in Immunology (2021)
  9. "B-cell biology and development" Journal of Allergy and Clinical Immunology (2013)